Edimer Pharmaceuticals
Cambridge
About Edimer Pharmaceuticals
Edimer Pharmaceuticals: Working toward improving the health and quality of life of families living with XLHED. Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $40.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2013)
- Website: edimerpharma.com
- Phone: (866)334-4240
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/edimer-pharmaceuticals-3081488 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.